Autoimmune Hemolytic Anemia Therapeutics Market

Autoimmune Hemolytic Anemia Therapeutics Market: Introduction

• Autoimmune hemolytic anemia (AHA) is also called immune hemolytic anemia. It is an immune and rare red blood cell disorder. Autoimmune hemolytic anemia occurs when the immune system makes antibodies that attack red blood cells in the body. This decreases the number of red blood cells, resulting to hemolytic anemia.
• Common symptoms of autoimmune hemolytic anemia include breathing difficulties, dark urine and/or splenomegaly, jaundice, and weakness & fatigue with tachycardia
• Autoimmune hemolytic anemia can be idiopathic or can result from medication or an underlying disease. Major types of autoimmune hemolytic anemia include cold antibody hemolytic anemia and warm antibody hemolytic anemia. Treatment for autoimmune hemolytic anemia can include splenectomy, corticosteroids such as prednisone, immunosuppressive drugs, and/or blood transfusions.

Key Drivers of Global Autoimmune Hemolytic Anemia Therapeutics Market

• The global autoimmune hemolytic anemia therapeutics market is primarily driven by increase in the use of drugs such as corticosteroids for patients with autoimmune hemolytic anemia. Corticosteroids are highly preferred to minimize complications such as osteoporosis, diabetes, obesity, and uncontrolled hypertension.
• Limited number of drugs are available for autoimmune hemolytic anemia treatment. This has encouraged biotechnology researchers and pharmaceutical companies to invest in research & development to develop novel therapies such as parsaclisib and fostamatinib.
• Additionally, rise in demand for the development of combination therapies and anemia therapeutics in patient assistance programs is expected to drive the global autoimmune hemolytic anemia therapeutics market

Corticosteroids Segment to Account for Major Share of Global Market

• Based on drug class, the global autoimmune hemolytic anemia therapeutics market can be classified into corticosteroids, monoclonal antibodies, and others
• The corticosteroids segment is anticipated to dominate the global market during the forecast period due to increase in the usage of corticosteroids for the treatment of autoimmune hemolytic anemia

Cold Antibody Hemolytic Anemia Segment to Offer Significant Opportunities

• In terms of disease type, the global autoimmune hemolytic anemia therapeutics market can be bifurcated into cold antibody hemolytic anemia and warm antibody hemolytic anemia
• The cold antibody hemolytic anemia segment is expected to account for major share of the global autoimmune hemolytic anemia therapeutics market by 2027
• The segment’s dominance can be attributed to large population of autoimmune hemolytic anemia suffering from cold antibody hemolytic anemia.

North America to Dominate Global Market

• In terms of region, the global autoimmune hemolytic anemia therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global autoimmune hemolytic anemia therapeutics market during the forecast period.
• Factors such as availability of patient assistance programs, increase in research & development activities for the development of novel therapies are anticipated to drive the autoimmune hemolytic anemia therapeutics market in North America

Key Players Operating in Global Market

The global autoimmune hemolytic anemia therapeutics market is highly fragmented, with a large number of domestic players accounting for majority of the market share. Key players operating in the global autoimmune hemolytic anemia therapeutics market are:

• Kezar Life Sciences, Inc.
• Amneal Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Rigel Pharmaceuticals, Inc.
• Baxter International, Inc.
• Incyte Corp.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer, Inc.
• Mylan NV

Global Autoimmune Hemolytic Anemia Therapeutics Market: Research Scope

Global Autoimmune Hemolytic Anemia Therapeutics Market, by Drug Class

• Corticosteroids
• Monoclonal Antibodies
• Others

Global Autoimmune Hemolytic Anemia Therapeutics Market, by Disease Type

• Cold Antibody Hemolytic Anemia
• Warm Antibody Hemolytic Anemia

Global Autoimmune Hemolytic Anemia Therapeutics Market, by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Autoimmune Hemolytic Anemia Therapeutics Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa